tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Hansa Biopharma to Discuss Q3 2025 Results in Upcoming Conference Call

Story Highlights
Hansa Biopharma to Discuss Q3 2025 Results in Upcoming Conference Call

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Hansa Biopharma AB ( (SE:HNSA) ) has shared an announcement.

Hansa Biopharma announced it will host a conference call to discuss its Q3 2025 interim results on October 30, 2025. The call, led by key executives, will cover the company’s financial performance and provide updates on its business and pipeline, reflecting its ongoing commitment to addressing serious medical needs in its field.

The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

More about Hansa Biopharma AB

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.

Average Trading Volume: 587,510

Technical Sentiment Signal: Buy

Current Market Cap: SEK3.3B

For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1